DR5-12D(DR5-12D) - 药物靶点：Na/K-ATPase_在研适应症：焦虑症_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名-

靶点

Na/K-ATPase

作用机制

Na/K-ATPase调节剂(钠钾转运ATP酶复合体调节剂)

治疗领域

其他疾病

在研适应症

焦虑症

非在研适应症-

原研机构

南方科技大学

在研机构

南方科技大学

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

关联

100 项与 DR5-12D 相关的临床结果

登录后查看更多信息

100 项与 DR5-12D 相关的转化医学

登录后查看更多信息

100 项与 DR5-12D 相关的专利（医药）

登录后查看更多信息

1

项与 DR5-12D 相关的文献（医药）

2024-03-01·Immunity

Disruption of the Na+/K+-ATPase-purinergic P2X7 receptor complex in microglia promotes stress-induced anxiety

Article

作者: Li, Kun ; Xiong, Siping ; Nie, Xiaowei ; Lin, Xiaoqian ; Xu, Kangtai ; Bian, Jin-Song ; Dong, Wanting ; Wang, Zilong ; Huang, Songqiang

Na⁺/K⁺-ATPase (NKA) plays an important role in the central nervous system. However, little is known about its function in the microglia. Here, we found that NKAα1 forms a complex with the purinergic P2X7 receptor (P2X7R), an adenosine 5'-triphosphate (ATP)-gated ion channel, under physiological conditions. Chronic stress or treatment with lipopolysaccharide plus ATP decreased the membrane expression of NKAα1 in microglia, facilitated P2X7R function, and promoted microglia inflammatory activation via activation of the NLRP3 inflammasome. Accordingly, global deletion or conditional deletion of NKAα1 in microglia under chronic stress-induced aggravated anxiety-like behavior and neuronal hyperexcitability. DR5-12D, a monoclonal antibody that stabilizes membrane NKAα1, improved stress-induced anxiety-like behavior and ameliorated neuronal hyperexcitability and neurogenesis deficits in the ventral hippocampus of mice. Our results reveal that NKAα1 limits microglia inflammation and may provide a target for the treatment of stress-related neuroinflammation and diseases.

100 项与 DR5-12D 相关的药物交易

登录后查看更多信息